Integrated Transcriptomic Analysis of Necrosis-related Gene in Diffuse Gliomas

Area of Science:

• Neuro-oncology
• Molecular Biology
• Genomics

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with pseudopalisading necrosis, a known prognostic indicator.
• The molecular mechanisms driving GBM progression, particularly related to necrosis, are not fully understood.
• Gene expression profiling offers a potential avenue for objective prognostic assessment in gliomas.

Purpose of the Study:

• To identify a gene expression signature for prognostic prediction in glioblastoma and low-grade glioma.
• To investigate the molecular mechanisms underlying GBM progression through differential gene expression analysis.
• To develop a novel prognostic index based on necrosis-related genes.

Main Methods:

• Utilized gene expression data from the Ivy Glioblastoma Atlas Project (IVY GAP) to identify differentially expressed genes in necrotic and non-necrotic GBM areas.
• Developed and validated a seven-gene signature using The Cancer Genome Atlas (TCGA) cohort for predicting patient risk in glioblastoma and low-grade glioma (GBM/LGG).
• Validated gene expression levels across TCGA, Repository for Molecular Brain Neoplasia Data (Rembrandt), and GSE16011 databases. Performed gene ontology, KEGG pathway, and gene set enrichment analyses on differentially expressed genes.

Main Results:

• A robust seven-gene signature was identified, capable of predicting glioblastoma and low-grade glioma patient outcomes.
• This signature effectively stratified patients into high-risk and low-risk groups in both training and validation cohorts.
• Enrichment analyses revealed that differentially expressed genes between risk groups are significantly associated with immune and inflammatory responses.

Conclusions:

• A novel seven-gene signature serves as a potential prognostic predictor for glioblastoma and low-grade glioma.
• The identified genes and their association with immune/inflammatory pathways offer insights into GBM progression.
• This signature may facilitate the development of targeted therapeutic strategies for brain tumors.